Cargando…
miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
α-synuclein is the synaptic protein majorly involved in neuronal dysfunction and death and it is well known for the last two decades as a hallmark of Parkinson’s disease. Alpha-synuclein is involved in neurodegeneration mediated through various neurotoxic pathways, majorly including autophagy or lys...
Autores principales: | Suvarna, Vasanti, Deshmukh, Kajal, Murahari, Manikanta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728483/ https://www.ncbi.nlm.nih.gov/pubmed/36506536 http://dx.doi.org/10.3389/fphar.2022.1034072 |
Ejemplares similares
-
Phytochemicals and PI3K Inhibitors in Cancer—An Insight
por: Suvarna, Vasanti, et al.
Publicado: (2017) -
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
por: Cole, Tracy A., et al.
Publicado: (2021) -
Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease
por: Uehara, Takuya, et al.
Publicado: (2019) -
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2017) -
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)